Objective To observe the efficacy and adverse reactions of afatinib in the second-line treatment of patients with advanced lung squamous cell carcinoma,and to explore the clinical value.Methods A total of 58 patients with ad-vanced lung squamoma with negative driver genes were collected from the First Affiliated Hospital of Bengbu Medical Uni-versity from March 2020 to October 2022 and afatinib was given orally at 40 mg/d according to the guidelines.When grade 3 or more side reactions occurred,the drug was stopped until the patients recovered,and the dose of re-administra-tion was reduced by 10 mg/time to the lowest 20 mg/d.The patients were evaluated every 6 weeks according to response evaluation criteria in solid tumor 1.1 until the disease progressed,and the therapeutic efficacy and adverse effects were observed.Results(1)Clinical efficacy:0 cases of complete remission,20 cases of partial remission(34.48％),18 cases of stable disease(31.04％),20 cases of progressive disease(34.48％),objective response rate(ORR)was 34.48％,disease control rate(DCR)65.52％;The median progression-free survival(mPFS)was 4.20 months(95％CI:3.62-4.78)and the median overall survival(mOS)was 11.60 months(95％CI:7.99-15.21).(2)Uni-variate results showed that PS score and underlying diseases were correlated with DCR,mPFS,and mOS,while non-sen-sitive gene mutation and distant metastasis were correlated with mPFS and mOS,and the differences were statistically sig-nificant(P＜0.05).(3)Multiple factors showed that PS score and underlying disease were risk factors for mPFS and mOS,and the differences were statistically significant(P＜0.05).(4)Adverse reactions:diarrhea in 58 cases(100.00％),skin rash in 44 cases(75.86％),and grade 3 adverse reactions,diarrhea in 7 cases(12.07％),skin rash in 5 cases(8.62％),no grade 3 or above adverse events.Conclusion Afatinib is an alternative second-line treat-ment for patients with advanced lung squamous cell carcinoma,with good efficacy and controllable side effects.
维普
万方数据
